{
    "organizations": [],
    "uuid": "7301438352f6519d6d543f287f6ef365989260f3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-axovant-announces-negative-results/brief-axovant-announces-negative-results-for-intepirdine-in-phase-2b-headway-pilot-phase-2-gait-balance-studies-idUSFWN1P30IV",
    "ord_in_thread": 0,
    "title": "BRIEF-Axovant Announces Negative Results For Intepirdine In Phase 2B Headway, Pilot Phase 2 Gait, Balance Studies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Axovant Sciences Ltd:\n* AXOVANT ANNOUNCES NEGATIVE RESULTS FOR INTEPIRDINE IN PHASE 2B HEADWAY AND PILOT PHASE 2 GAIT AND BALANCE STUDIES; POSITIVE TRENDS IN EFFICACY SEEN IN PILOT PHASE 2 NELOTANSERIN STUDY\n* AXOVANT SCIENCES LTD - INTEPIRDINE PROGRAM TO BE DISCONTINUED BASED ON MINDSET, HEADWAY, AND GAIT AND BALANCE STUDY RESULTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T20:10:00.000+02:00",
    "crawled": "2018-01-09T17:03:57.038+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "axovant",
        "science",
        "ltd",
        "axovant",
        "announces",
        "negative",
        "result",
        "intepirdine",
        "phase",
        "2b",
        "headway",
        "pilot",
        "phase",
        "gait",
        "balance",
        "study",
        "positive",
        "trend",
        "efficacy",
        "seen",
        "pilot",
        "phase",
        "nelotanserin",
        "study",
        "axovant",
        "science",
        "ltd",
        "intepirdine",
        "program",
        "discontinued",
        "based",
        "mindset",
        "headway",
        "gait",
        "balance",
        "study",
        "result",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}